Log In
Print
BCIQ
Print
Print this Print this
 

safinamide (formerly PNU-151774E)

  Manage Alerts
Collapse Summary General Information
Company Newron Pharmaceuticals S.p.A.
DescriptionAlpha-aminoamide derivative that acts as a reversible monoamine oxidase B (MAO-B) and dopamine reuptake inhibitor while reducing glutamatergic activity
Molecular Target Monoamine oxidase B (MAO-B)
Mechanism of ActionMonoamine oxidase B (MAO-B) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentRegistration
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat early Parkinson's disease (PD); Treat mid- to late-stage Parkinson's disease (PD); Treat Parkinson's disease (PD)
Regulatory Designation

Partner

Meiji Seika Pharma Co. Ltd.; Zambon Co. S.p.A.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today